CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
1.5. EXECUTIVE SUMMARY
1.6. CXO PERSPECTIVE
CHAPTER 2 MARKET OVERVIEW
2.1. MARKET DEFINITION AND SCOPE
2.2. KEY FINDINGS
2.2.1. Top investment pockets
2.2.2. Top winning stratgies
2.3. MARKET SHARE ANALYSIS,2016
2.4. PORTERS FIVE FORCES ANALYSIS
2.5. MARKET DYNAMICS
2.5.1. Drivers
2.5.1.1. Increase in geriatric population
2.5.1.2. Rise in prevalence of neurological & epidemic disorders
2.5.1.3. Launch of innovative products for nerve repair & regeneration
2.5.2. Restraints
2.5.2.1. Stringent regulatory requirements for product approvals
2.5.3. Opportunities
2.5.3.1. Increase in peripheral nerve injuries and neurological disorders
2.5.3.2. Improvement in the healthcare facilities in Asia-Pacific
CHAPTER 3 NERVE REPAIR AND REGENERATION MARKET, BY PRODUCT
3.1. OVERVIEW
3.2. BIOMATERIAL
3.2.1. Key market trends
3.2.2. Key growth factors and opportunities
3.2.3. Market size and forecast
3.2.4. Nerve Conduits
3.2.4.1. Market size and forecast
3.2.5. Nerve Protectors
3.2.5.1. Market size and forecast
3.2.6. Nerve Wraps
3.2.6.1. Market size and forecast
3.2.7. Nerve Connectors
3.2.7.1. Market size and forecast
3.3. NEUROMODULATION SURGERY DEVICES
3.3.1. Key market trends
3.3.2. Key growth factors and opportunities
3.3.3. Market size and forecast
3.3.4. External neuromodulation devices
3.3.4.1. Market size and forecast
3.3.4.2. Transcutaneous Electrical Nerve Stimulation
3.3.4.3. Transcranial Magnetic Stimulation
3.3.5. Internal neuromodulation surgery
3.3.5.1. Market size and forecast
3.3.5.2. Spinal Cord Stimulation
3.3.5.2.1. Market size and forecast
3.3.5.3. Deep Brain Stimulation
3.3.5.3.1. Market size and forecast
3.3.5.4. Sacral Nerve Stimulation
3.3.5.4.1. Market size and forecast
3.3.5.5. Vagus Nerve Stimulation
3.3.5.5.1. Market size and forecast
3.3.5.6. Others
3.3.5.6.1. Market size and forecast
CHAPTER 4 NERVE REPAIR AND REGENERATION MARKET, BY SURGERIES
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. DIRECT NEUROPATHY
4.2.1. Market size and forecast
4.2.2. Epineural Repair
4.2.2.1. Market size and forecast
4.2.3. Perineural Repair
4.2.3.1. Market size and forecast
4.2.4. Group Fascicular Repair
4.2.4.1. Market size and forecast
4.3. NERVE GRAFTING
4.3.1. Market size and forecast
4.3.2. Autografts
4.3.2.1. Market size and forecast
4.3.3. Allografts
4.3.3.1. Market size and forecast
4.3.4. Xenografts
4.3.4.1. Market size and forecast
4.4. STEM CELL THERAPY
4.4.1. Market size and forecast
4.5. NEUROMODULATION SURGERY
4.5.1. Market size and forecast
4.5.2. External Neuromodulation Surgery
4.5.2.1. Market size and forecast
4.5.3. Internal Neuromodulation Surgery
4.5.3.1. Market size and forecast
CHAPTER 5 NERVE REPAIR AND REGENERATION MARKET, BY GEOGRAPHY
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. NORTH AMERICA
5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast
5.2.4. U.S.: market size and forecast
5.2.5. Canada: market size and forecast
5.2.6. Mexico: market size and forecast
5.3. EUROPE
5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast
5.3.4. Germany: market size and forecast
5.3.5. France market size and forecast
5.3.6. UK: market size and forecast
5.3.7. Italy: market size and forecast
5.3.8. Spain: market size and forecast
5.3.9. Rest of Europe: market size and forecast
5.4. ASIA-PACIFIC
5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast
5.4.4. Japan: market size and forecast
5.4.5. China market size and forecast
5.4.6. India: market size and forecast
5.4.7. Rest of Asia-Pacific market size and forecast
5.5. LAMEA
5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast
5.5.4. Latin America: market size and forecast
5.5.5. Middle East market size and forecast
5.5.6. Africa: market size and forecast
CHAPTER 6 COMPANY PROFILES
6.1. AXOGEN INC.
6.1.1. Overview
6.1.2. Operating business segments
6.1.3. Business performance
6.2. BAXTER INTERNATIONAL
6.2.1. Overview
6.2.2. Operating business segments
6.2.3. Business performance
6.2.4. Key strategic moves & developments
6.3. BOSTON SCIENTIFIC INCORPORATION
6.3.1. OVERVIEW
6.3.2. Operating business segments
6.3.3. Business performance
6.3.4. Key strategic moves & developments
6.4. CYBERONICS INC.
6.4.1. Overview
6.4.2. Operating business segments
6.4.3. Business performance
6.4.4. Key strategic moves & developments
6.5. INTEGRA LIFESCIENCES CORPORATION
6.5.1. Overview
6.5.2. Operating business segments
6.5.3. Business performance
6.5.4. Key strategic moves & developments
6.6. MEDTRONIC PLC
6.6.1. Overview
6.6.2. Operating business segments
6.6.3. Business performance
6.7. ORTHOMED S.A.S.
6.7.1. Overview
6.7.2. Operating business segments
6.7.3. Business performance
6.8. POLYGANICS B.V.
6.8.1. OVERVIEW
6.8.2. Operating business segments
6.8.3. Business performance
6.9. ST. JUDE MEDICAL
6.9.1. Overview
6.9.2. Operating business segments
6.9.3. Business performance
6.9.4. Key strategic moves & developments
6.10. STRYKER CORPORATION
6.10.1. Overview
6.10.2. Operating business segments
6.10.3. Business performance